Stayble Therapeutics AB (OSTO:STABL) Debt-to-Revenue : N/A (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Stayble Therapeutics AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Stayble Therapeutics AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr0.00 Mil. Stayble Therapeutics AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr0.00 Mil. Stayble Therapeutics AB's annualized Revenue for the quarter that ended in Sep. 2024 was kr0.00 Mil.

Stayble Therapeutics AB Debt-to-Revenue Historical Data

The historical data trend for Stayble Therapeutics AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stayble Therapeutics AB Debt-to-Revenue Chart

Stayble Therapeutics AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

Stayble Therapeutics AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Jun24	Sep24
Debt-to-Revenue	Get a 7-Day Free Trial															N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Stayble Therapeutics AB's Debt-to-Revenue

For the Biotechnology subindustry, Stayble Therapeutics AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stayble Therapeutics AB's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Stayble Therapeutics AB's Debt-to-Revenue falls into.

Stayble Therapeutics AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Stayble Therapeutics AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	N/A
	=	N/A

Stayble Therapeutics AB's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.

Stayble Therapeutics AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Stayble Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (OSTO:STABL) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lennart Torstenssonsgatan 6, Gothenburg, SWE, 412 56

Website

https://www.staybletherapeutics.com

Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB Headlines

No Headlines